Renewal of the Hematology-Oncology Associates of Central New York (HOACNY) CCOP grant will enable us to continue to participate in NCI sponsored treatment and cancer control studies. We are currently following hundreds of patients on treatment trials and cancer control and prevention trials. Continuation of the grant will not only enable us to continue to follow these patients but to accrue additional individuals to such studies. Our clinical research department continues to work closely with the entire staff of HOACNY to identify eligible patients for treatment and symptom control studies. We actively recruit high-risk individuals from a large area of Central New York for cancer prevention studies. We have greatly expanded the participants in our CCOP (14 full time medical and radiation oncologists with 3 more to join soon), which will better serve our geographical region. The availability of a wide range of treatment and cancer control protocols improves the overall care of cancer patients in our community. The entire CCOP staff continues to not only provide """"""""state of the art"""""""" care to our patients but also serves as a valuable resource to local health care providers and educates the entire CNY community in terms of cancer treatment and prevention. Our goal is to maintain the CCOP at a high level in terms of quantity and quality and to further increase our efforts in terms of cancer prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045389-24
Application #
7847704
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Kelaghan, Joseph
Project Start
1987-07-21
Project End
2014-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
24
Fiscal Year
2010
Total Cost
$534,356
Indirect Cost
Name
Hematology-Oncology Associates/Ctl NY
Department
Type
DUNS #
101317097
City
East Syracuse
State
NY
Country
United States
Zip Code
13057
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20

Showing the most recent 10 out of 66 publications